These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 7522382)

  • 21. Use of intrinsic and extrinsic helper epitopes for in vivo induction of anti-hepatitis C virus cytotoxic T lymphocytes (CTL) with CTL epitope peptide vaccines.
    Shirai M; Chen M; Arichi T; Masaki T; Nishioka M; Newman M; Nakazawa T; Feinstone SM; Berzofsky JA
    J Infect Dis; 1996 Jan; 173(1):24-31. PubMed ID: 8537666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Temporal loss of Nef-epitope CTL recognition following macaque lipopeptide immunization and SIV challenge.
    Mortara L; Letourneur F; Villefroy P; Beyer C; Gras-Masse H; Guillet JG; Bourgault-Villada I
    Virology; 2000 Dec; 278(2):551-61. PubMed ID: 11118377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene.
    Weijer K; Pfauth A; van Herwijnen R; Jarrett O; Meloen RH; Tomee C; Osterhaus AD
    Vaccine; 1993; 11(9):946-56. PubMed ID: 7692683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Producing a highly immunogenic synthetic vaccine construct active against HIV-1 subtype C.
    Hewer R; Meyer D
    Vaccine; 2002 Jun; 20(21-22):2680-3. PubMed ID: 12034093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of B-cell epitopes in the envelope glycoproteins of simian immunodeficiency virus.
    Benichou S; Venet A; Beyer C; Tiollais P; Madaule P
    Virology; 1993 Jun; 194(2):870-4. PubMed ID: 7684879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
    J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced cellular immune responses to SIV Gag by immunization with influenza and vaccinia virus recombinants.
    Nakaya Y; Zheng H; García-Sastre A
    Vaccine; 2003 May; 21(17-18):2097-106. PubMed ID: 12706700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity of neutralizing epitopes on multiple-epitope vaccines against HIV-1.
    Lu Y; Xiao Y; Ding J; Dierich M; Chen YH
    Int Arch Allergy Immunol; 2000 Jan; 121(1):80-4. PubMed ID: 10686512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A MHC class I B locus allele-restricted simian immunodeficiency virus envelope CTL epitope in rhesus monkeys.
    Yasutomi Y; McAdam SN; Boyson JE; Piekarczyk MS; Watkins DI; Letvin NL
    J Immunol; 1995 Mar; 154(5):2516-22. PubMed ID: 7532670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo.
    Stahl-Hennig C; Coulibaly C; Petry H; Voss G; Dittmer U; Bodemer W; Makoschey B; Jurkiewicz E; Lüke W; Hunsmann G
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S27-32. PubMed ID: 7865316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current approaches to vaccination against human immunodeficiency viruses.
    Gluckman JC; Yagello M; Bahraoui E; Girard M
    Allergol Immunopathol (Madr); 1991; 19(1):11-3. PubMed ID: 1719790
    [No Abstract]   [Full Text] [Related]  

  • 32. Antibodies to the putative SIV infection-enhancing domain diminish beneficial effects of an SIV gp160 vaccine in rhesus macaques.
    Mitchell WM; Torres J; Johnson PR; Hirsch V; Yilma T; Gardner MB; Robinson WE
    AIDS; 1995 Jan; 9(1):27-34. PubMed ID: 7893438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants.
    Gonzalo RM; Rodríguez D; García-Sastre A; Rodríguez JR; Palese P; Esteban M
    Vaccine; 1999 Feb; 17(7-8):887-92. PubMed ID: 10067695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity of a vaccine preparation representing the variable regions of the HIV type 1 envelope glycoprotein.
    Carlos MP; Anderson DE; Gardner MB; Torres JV
    AIDS Res Hum Retroviruses; 2000 Jan; 16(2):153-61. PubMed ID: 10659054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A conformational C4 peptide polymer vaccine coupled with live recombinant vector priming is immunogenic but does not protect against rectal SIV challenge.
    Patterson LJ; Robey F; Muck A; Van Remoortere K; Aldrich K; Richardson E; Alvord WG; Markham PD; Cranage M; Robert-Guroff M
    AIDS Res Hum Retroviruses; 2001 Jun; 17(9):837-49. PubMed ID: 11429125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide.
    Frangione-Beebe M; Albrecht B; Dakappagari N; Rose RT; Brooks CL; Schwendeman SP; Lairmore MD; Kaumaya PT
    Vaccine; 2000 Dec; 19(9-10):1068-81. PubMed ID: 11137241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The simian immunodeficiency virus transmembrane protein is poorly immunogenic in inactivated virus vaccine.
    Cranage MP; McBride BW; Rud EW
    Vaccine; 1995 Jul; 13(10):895-900. PubMed ID: 7483761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity of hybrid DNA vaccines expressing hepatitis B core particles carrying human and simian immunodeficiency virus epitopes in mice and rhesus macaques.
    Fuller DH; Shipley T; Allen TM; Fuller JT; Wu MS; Horton H; Wilson N; Widera G; Watkins DI
    Virology; 2007 Aug; 364(2):245-55. PubMed ID: 17428516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protection against SIV infection in macaques by immunization with inactivated virus from the BK28 molecular clone, but not with BK28-derived recombinant env and gag proteins.
    Mills KH; Page M; Chan WL; Kitchin P; Stott EJ; Taffs F; Jones W; Rose J; Ling C; Silvera P
    J Med Primatol; 1992; 21(2-3):50-8. PubMed ID: 1433267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein.
    Liang X; Munshi S; Shendure J; Mark G; Davies ME; Freed DC; Montefiori DC; Shiver JW
    Vaccine; 1999 Jul; 17(22):2862-72. PubMed ID: 10438057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.